For U.S. Healthcare Professionals Only

Visit Sanofi U.S.:

 

 

Fabry disease is an X-linked, multi-systemic, genetic disorder of glycosphingolipid metabolism. Clinical manifestations are due to absence / deficiency of lysosomal α-Galactosidase A activity, the result of pathogenic mutations in GLA.1

Fabry disease patients are typically classified as “classic” or “non-classic”, often referred to as “late-onset”:

  • Classic males primarily present in childhood or adolescence with neuropathic pain, angiokeratomas, corneal opacities, hypohidrosis, and GI disturbances. In adulthood, patients with classic disease are at risk for kidney failure, cardiomyopathy, cardiovascular disease, arrhythmias, and stroke/TIA.2
  • Organ damage often begins without overt symptoms, particularly in females, and may become irreversible and potentially life-threatening3,4
  • Non-classic patients present with variable age of onset and manifestations, most commonly seen in the 4th to 7th decades and may be initially limited to single-organ involvement.2
  • Phenotypic heterogeneity and overlap with more common conditions can make predicting genotype:phenotype correlations challenging.2

Female Fabry patients have a wide spectrum of disease manifestations from asymptomatic to a severe phenotype similar to classic males.1

  • 70–100% of females heterozygous for pathogenic Fabry disease mutations develop symptoms; they are not “carriers”.1, 5-6

 

To review publications on Fabry disease, click here
 

Inheritance

As an X-linked disease, the genetic defect that causes Fabry disease can be transmitted by both males and females1, 7-8

  • Sons with a pathogenic GLA mutation are affected
  • Daughters with a pathogenic GLA mutation can have variable clinical severity, ranging from asymptomatic to severe disease due to X-inactivation

 

 segregation of x linked trait

1. Germain DP. Orphanet J Rare Dis 2010;5:30; 2. Ortiz A, et al. Mol Genet Metab. 2018;123:416-427. 3. Moura LA, et al. ASN Kidney Week 2017; Abstract SA-PO628;
4. Niemann M, et al. JACC Cardiovasc Imaging 2011; 4:592-601; 5.Wang RY, et al. Genet Med 2007;9:34–45; 6. Dobyns WB. Acta Paediatr 2006;95(Suppl):11–15.
7. Desnick RJ, et al. α-Galactosidase A Deficiency: Fabry Disease. In: Valle D, et al; eds. New York, NY. McGraw Hill, 2001; 8. Echeverria L, et al. Clin Genet 2016;89:44

 

 

 

 

 

Last Updated: Jan 30, 2020
What's New

What's New

New to molecular testing?
This 4 minute video illustrates the path a healthcare provider takes when ordering diagnostic testing for a lysosomal storage disease for the first time, and offers tips along the way.

Contact

Contact

Contact the Rare Diseases Medical Affairs team

Event Calendar

Event Calendar

Find Upcoming Events and Presentations on Our Event Calendar